Related Experiment Video
Updated: Aug 14, 2025
09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
Alzheimer's Disease Is a Multi-Organ Disorder: It May Already Be Preventable
Arnold R Eiser1,2, Tamas Fulop3
1Penn Center for Public Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Journal of Alzheimer'S Disease : JAD
|January 9, 2023
Summary
Environmental and metabolic factors, including immune dysfunction, gut dysbiosis, and toxins, contribute to Alzheimer's disease (AD). Early detection and correction of these factors are crucial for prevention and treatment.
Area of Science:
- Neuroscience
- Environmental Health
- Metabolic Disorders
Background:
- Alzheimer's disease (AD) development is multifactorial.
- Extracranial organ systems significantly influence AD pathogenesis.
Purpose of the Study:
- To overview environmental and metabolic factors implicated in Alzheimer's disease.
- To highlight the role of extracranial organ systems and microbial factors in AD.
Main Methods:
- Review of existing literature on environmental and metabolic contributors to AD.
- Analysis of the interplay between systemic health and neuroinflammation.
Main Results:
- Immune dysfunction (inflammaging), gut dysbiosis, insulin resistance, and hepatic dysfunction are key factors.
- Microbial factors (oral flora, viruses, fungi) and environmental toxins (metals) play significant roles.
- Dysbiosis and toxins impair the blood-brain barrier and exacerbate neuroinflammation.
Conclusions:
- AD prevention and treatment necessitate biomarker assessment for environmental toxicants and metabolic dysfunction.
- Intervention at early or preclinical stages is critical for managing AD.
- Addressing extracranial factors offers a promising therapeutic avenue for Alzheimer's disease.
Keywords:
Alzheimer’s diseasebiotoxinsdementiadysbiosisenvironmental exposuremetabolismneuroinflammationMore Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
600
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
600
01:22Alzheimer's Disease: Treatment
238
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
238
01:15Parkinson's Disease: Overview
645
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
645
01:30Dementia
153
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
153
01:28Disorders of the Nervous Tissue
1.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.5K
01:26Atherosclerosis III: Management
19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19